{"id":5247,"date":"2023-04-27T04:17:35","date_gmt":"2023-04-27T04:17:35","guid":{"rendered":"https:\/\/healthnewscentral.com\/?p=5247"},"modified":"2023-04-27T04:17:35","modified_gmt":"2023-04-27T04:17:35","slug":"fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer","status":"publish","type":"post","link":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/","title":{"rendered":"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer"},"content":{"rendered":"
\"\"
Fierce Pharma<\/figcaption><\/figure>\n

In clinical trials made, scientists saw that those who took Trodelvy had better survival rates, especially for those who have been diagnosed with HR-positive\/HER2-negative breast cancer. The drug was previously cleared for triple-negative tumors has also been approved for HR-positive\/HER2-negative breast cancer.<\/p>\n

Yes, it\u2019s good news for those diagnosed with the most common subtype of breast cancer. They now have a new choice because the U.S. Food and Drug Administration (FDA) has expanded its approval of the oncology drug called sacituzumab govitecan (Trodelvy) for advanced hormone receptor (HR)\u2013positive, human epidermal growth factor receptor 2 (HER2)\u2013negative (HR-positive\/HER2-negative) tumors.<\/p>\n

Trodelvy for oftentimes prescribed for adult patients with advanced HR-positive\/HER2-negative breast cancer that can\u2019t be addressed with just surgery and that with growth that hasn\u2019t been eradicated by chemotherapy or endocrine therapy. The latter was made to disrupt the hormones that promote tumor growth, as per Gilead Sciences<\/a>, the company that developed the drug.<\/p>\n

When it comes to breast cancer, HR-positive\/HER2-negative tumors are the most common subtype, according to the\u00a0National Cancer Institute (NCI)<\/a>. Most, if not all, patients survive at least five years when this is caught in its early stages, and more than 90 percent of the patients live long when the tumors have only spread to some surrounding tissue near the breast, said the experts from the NCI.<\/p>\n

Unfortunately, the five-year survival rate drops to around 32 percent when these tumors have metastasized, or spread to more further tissues and organs.<\/p>\n

\u201cTrodelvy will certainly change the treatment landscape\u201d for advanced HR-positive\/HER2-negative breast cancer,\u201d<\/strong><\/em> Kiven Erique Lukong, PhD<\/a> said. She is a professor and a breast cancer researcher at the\u00a0University of Saskatchewan College of Medicine in Canada. She, however, was not part of the trials for the new approval. \u201cIt will benefit patients with metastasis who have exhausted all previous treatment options including surgery.\u201d<\/strong><\/em><\/p>\n

According to Experts: Trodelvy Fills in the Gap in Breast Cancer Treatment<\/h2>\n

Trodelvy could help stop tumor growth, ease the symptoms so patients enjoy a better quality of life, and also extend survival times, said Hope Rugo, MD<\/a>. She is a professor of medicine and director of breast oncology and clinical trials education at the University of California San Francisco Comprehensive Cancer Center.<\/p>\n

\u201cWe run out of treatment options long before many patients are ready to stop therapy \u2014 they still have good quality of life and organ function,\u201d<\/strong><\/em> Dr. Rugo said. She is the lead author of a pivotal clinical trial the FDA reviewed before approving Trodelvy for people with advanced HR-positive\/HER2-negative breast cancer.<\/p>\n

Trodelvy<\/a>\u00a0belongs to a family of drugs known as antibody-drug conjugates. Included on this list is an anti-cancer drug and an antibody that fights an antigen, or toxin in the immune system. This plays a vital part in certain types of cancer.<\/p>\n

The FDA approved Trodelvy in 2020 as well for those who have been diagnosed with triple-negative breast cancer. This type involves tumors that don\u2019t have\u00a0estrogen\u00a0or\u00a0progesterone\u00a0receptors and make little or none of the protein HER2.<\/p>\n

<\/h2>\n

Trodelvy Showed Better Outcome than Just Chemotherapy Alone<\/h2>\n

Researchers started to look into the application of the drug for other\u00a0types of breast cancer, and presented preliminary late-stage results from the ongoing\u00a0TROPiCS-02 trial<\/a>\u00a0last June at the 2022 conference of the\u00a0American Society of Clinical Oncology (ASCO)<\/a>. A total of 543 patients in the trial were diagnosed with advanced HR-positive\/HER2-negative breast cancer. These patients have already been prescribed with multiple courses of chemotherapy, hormone therapy, and other types of drugs that target cancer.<\/p>\n

What the researchers did was randomly assign patients to receive either of the 2 things: chemotherapy or Trodelvy and continue treatment until side effects nulled further treatment or when the tumors spread once more. The median time without tumor growth, a period that was shorter for 50 percent of the patients and longer for the 50 percent, was 5.5 months with Trodelvy and 4 months with chemotherapy, as per interim trial results last January 2022.<\/p>\n

With the use of Trodelvy, 46 percent of the patients had no tumor progression at six months while 21 percent still had no tumor recurrence after a year, the interim analysis saw. In comparison, 30 percent of chemotherapy patients had no cancer progression at six months, and 7 percent saw no tumor recurrence at a year.<\/p>\n

Additional results were presented at the 2022 ESMO Congress<\/a>\u00a0and the results were able to present a clear survival advantage when Trodelvy is used. This analysis was based on interim results as of July 2022 and they found that patients survived a median of 14.4 months on Trodelvy when placed side by side of 11.2 months on chemotherapy.<\/p>\n

Most patients reported to have experienced side effects, which made an impact on 74 percent of those on Trodelvy and 60 percent on chemotherapy, as per the results presented at ASCO. Neutropenia, or dangerously low levels of white blood cells, had been the most reported serious side effect. This affected 51 percent of patients on Trodelvy. Other effects reported were diarrhea, which impacted around 10 percent. As for the treatment-related death reports, there had been one in the group that took Trodelvy.<\/p>\n

Because of its risks of neutropenia and diarrhea, Trodelvy comes with a black box warning, which is the FDA\u2019s strictest<\/a>.<\/p>\n

\n","protected":false},"excerpt":{"rendered":"

In clinical trials made, scientists saw that those who took Trodelvy had better survival rates, especially for those who have been diagnosed with HR-positive\/HER2-negative breast cancer. The drug was previously cleared for triple-negative tumors has also been approved for HR-positive\/HER2-negative breast cancer. Yes, it\u2019s good news for those diagnosed with the most common subtype of […]<\/p>\n","protected":false},"author":9,"featured_media":5248,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"image","meta":[],"categories":[4],"tags":[476,1080,16,1567],"yoast_head":"\nFDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer<\/title>\n<meta name=\"description\" content=\"In clinical trials made, scientists saw that those who took Trodelvy had better survival rates, especially for those who have breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"In clinical trials made, scientists saw that those who took Trodelvy had better survival rates, especially for those who have breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Health News Central\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T04:17:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/healthnewscentral.com\/wp-content\/uploads\/2023\/03\/Trodelvy.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"730\" \/>\n\t<meta property=\"og:image:height\" content=\"465\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"katcruz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"katcruz\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/\"},\"author\":{\"name\":\"katcruz\",\"@id\":\"https:\/\/healthnewscentral.com\/#\/schema\/person\/38b633af813eb345a6ed540cc63d452f\"},\"headline\":\"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer\",\"datePublished\":\"2023-04-27T04:17:35+00:00\",\"dateModified\":\"2023-04-27T04:17:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/\"},\"wordCount\":898,\"publisher\":{\"@id\":\"https:\/\/healthnewscentral.com\/#organization\"},\"keywords\":[\"breast cancer\",\"FDA\",\"health\",\"Trodelvy\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/\",\"url\":\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/\",\"name\":\"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer\",\"isPartOf\":{\"@id\":\"https:\/\/healthnewscentral.com\/#website\"},\"datePublished\":\"2023-04-27T04:17:35+00:00\",\"dateModified\":\"2023-04-27T04:17:35+00:00\",\"description\":\"In clinical trials made, scientists saw that those who took Trodelvy had better survival rates, especially for those who have breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/healthnewscentral.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/healthnewscentral.com\/#website\",\"url\":\"https:\/\/healthnewscentral.com\/\",\"name\":\"Health News Central\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/healthnewscentral.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/healthnewscentral.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/healthnewscentral.com\/#organization\",\"name\":\"Health News Central\",\"url\":\"https:\/\/healthnewscentral.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/healthnewscentral.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/healthnewscentral.com\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-06-at-6.14.51-AM.png\",\"contentUrl\":\"https:\/\/healthnewscentral.com\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-06-at-6.14.51-AM.png\",\"width\":1396,\"height\":484,\"caption\":\"Health News Central\"},\"image\":{\"@id\":\"https:\/\/healthnewscentral.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/healthnewscentral.com\/#\/schema\/person\/38b633af813eb345a6ed540cc63d452f\",\"name\":\"katcruz\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/healthnewscentral.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/85d53048a5155d19ec8889113281bc78?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/85d53048a5155d19ec8889113281bc78?s=96&d=mm&r=g\",\"caption\":\"katcruz\"},\"url\":\"https:\/\/healthnewscentral.com\/author\/katcruz\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer","description":"In clinical trials made, scientists saw that those who took Trodelvy had better survival rates, especially for those who have breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer","og_description":"In clinical trials made, scientists saw that those who took Trodelvy had better survival rates, especially for those who have breast cancer.","og_url":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/","og_site_name":"Health News Central","article_published_time":"2023-04-27T04:17:35+00:00","og_image":[{"width":730,"height":465,"url":"https:\/\/healthnewscentral.com\/wp-content\/uploads\/2023\/03\/Trodelvy.webp","type":"image\/webp"}],"author":"katcruz","twitter_card":"summary_large_image","twitter_misc":{"Written by":"katcruz","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/"},"author":{"name":"katcruz","@id":"https:\/\/healthnewscentral.com\/#\/schema\/person\/38b633af813eb345a6ed540cc63d452f"},"headline":"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer","datePublished":"2023-04-27T04:17:35+00:00","dateModified":"2023-04-27T04:17:35+00:00","mainEntityOfPage":{"@id":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/"},"wordCount":898,"publisher":{"@id":"https:\/\/healthnewscentral.com\/#organization"},"keywords":["breast cancer","FDA","health","Trodelvy"],"articleSection":["Health"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/","url":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/","name":"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer","isPartOf":{"@id":"https:\/\/healthnewscentral.com\/#website"},"datePublished":"2023-04-27T04:17:35+00:00","dateModified":"2023-04-27T04:17:35+00:00","description":"In clinical trials made, scientists saw that those who took Trodelvy had better survival rates, especially for those who have breast cancer.","breadcrumb":{"@id":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/healthnewscentral.com\/fda-finally-approves-the-use-of-trodelvy-to-treat-the-most-common-type-of-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/healthnewscentral.com\/"},{"@type":"ListItem","position":2,"name":"FDA Finally Approves The Use Of Trodelvy To Treat The Most Common Type Of Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/healthnewscentral.com\/#website","url":"https:\/\/healthnewscentral.com\/","name":"Health News Central","description":"","publisher":{"@id":"https:\/\/healthnewscentral.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/healthnewscentral.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/healthnewscentral.com\/#organization","name":"Health News Central","url":"https:\/\/healthnewscentral.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/healthnewscentral.com\/#\/schema\/logo\/image\/","url":"https:\/\/healthnewscentral.com\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-06-at-6.14.51-AM.png","contentUrl":"https:\/\/healthnewscentral.com\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-06-at-6.14.51-AM.png","width":1396,"height":484,"caption":"Health News Central"},"image":{"@id":"https:\/\/healthnewscentral.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/healthnewscentral.com\/#\/schema\/person\/38b633af813eb345a6ed540cc63d452f","name":"katcruz","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/healthnewscentral.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/85d53048a5155d19ec8889113281bc78?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/85d53048a5155d19ec8889113281bc78?s=96&d=mm&r=g","caption":"katcruz"},"url":"https:\/\/healthnewscentral.com\/author\/katcruz\/"}]}},"_links":{"self":[{"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/posts\/5247"}],"collection":[{"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/comments?post=5247"}],"version-history":[{"count":2,"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/posts\/5247\/revisions"}],"predecessor-version":[{"id":5387,"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/posts\/5247\/revisions\/5387"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/media\/5248"}],"wp:attachment":[{"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/media?parent=5247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/categories?post=5247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthnewscentral.com\/wp-json\/wp\/v2\/tags?post=5247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}